In this issue:
Neoadjuvant plus adjuvant treatment of melanoma
Neoadjuvant therapy with ICI combinations
SNB assists in decision-making for adjuvant treatment
CP-GEP use to identify high-risk stage I/IIA melanoma
VEGFR-2 inhibitors plus anti-PD1 in acral melanoma
Anti-androgen therapy in PD1 failures
SSM in relation to age
Circular RNAs in melanoma prognosis
Multiple melanoma and prostate carcinoma
Host and tumour factors in response to anti-PD1 therapy
Please login below to download this issue (PDF)